Contrasting PURE Bioscience (OTCMKTS:PURE) & LeMaitre Vascular (NASDAQ:LMAT)

PURE Bioscience (OTCMKTS:PURE) and LeMaitre Vascular (NASDAQ:LMAT) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, earnings, valuation, dividends, institutional ownership, profitability and risk.

Volatility and Risk

PURE Bioscience has a beta of 0.16, indicating that its share price is 84% less volatile than the S&P 500. Comparatively, LeMaitre Vascular has a beta of 0.54, indicating that its share price is 46% less volatile than the S&P 500.

Profitability

This table compares PURE Bioscience and LeMaitre Vascular’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
PURE Bioscience	-109.59%	N/A	-321.74%
LeMaitre Vascular	24.35%	15.36%	9.78%

Analyst Recommendations

This is a summary of recent ratings and price targets for PURE Bioscience and LeMaitre Vascular, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PURE Bioscience	0	0	0	0	0.00
LeMaitre Vascular	0	3	4	1	2.75

LeMaitre Vascular has a consensus price target of $112.60, suggesting a potential upside of 19.88%. Given LeMaitre Vascular’s stronger consensus rating and higher possible upside, analysts clearly believe LeMaitre Vascular is more favorable than PURE Bioscience.

Valuation & Earnings

This table compares PURE Bioscience and LeMaitre Vascular”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PURE Bioscience	$2.20 million	4.12	-$2.40 million	($0.03)	-2.32
LeMaitre Vascular	$249.60 million	8.60	$57.73 million	$2.71	34.66

LeMaitre Vascular has higher revenue and earnings than PURE Bioscience. PURE Bioscience is trading at a lower price-to-earnings ratio than LeMaitre Vascular, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

84.6% of LeMaitre Vascular shares are held by institutional investors. 35.6% of PURE Bioscience shares are held by insiders. Comparatively, 7.4% of LeMaitre Vascular shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

LeMaitre Vascular beats PURE Bioscience on 14 of the 15 factors compared between the two stocks.

About PURE Bioscience

PURE Bioscience, Inc. develops and commercializes antimicrobial products that provide solutions to the health and environmental challenges of pathogen and hygienic control in the United States and internationally. The company manufactures and distributes silver dihydrogen citrate (SDC), a non-toxic antimicrobial agent, which offers residual protection, as well as formulates with other compounds. It offers SDC-based disinfecting and sanitizing products, including PURE Hard Surface, a food contact surface sanitizer and disinfectant; PURE Control, a food contact processing aid for fresh produce and raw poultry; PURE Multi-Purpose and Floor Cleaner Concentrate to clean various resilient surfaces, including floors, glass, and food contact surfaces; and PURE Multi-Purpose Hi-Foam Cleaner Concentrate to clean stainless steel equipment, resilient floors, walls, and painted surfaces. The company also provides Axen30, a hard surface disinfectant; Axenohl, an antimicrobial formulation for use as a raw material ingredient in the manufacturing of consumer and commercial disinfecting and sanitizing products; and SILVÉRION, an antimicrobial formulation that is used against bacteria, viruses, yeasts, and molds. PURE Bioscience, Inc. was incorporated in 1992 and is headquartered in Rancho Cucamonga, California.

About LeMaitre Vascular

LeMaitre Vascular, Inc. develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature. The company also provides artegraft biologic graft, a bovine carotid artery used for dialysis access; XenoSure biologic patches, used for closure of vessels after surgical intervention; VascuCel and CardioCel biologic patches, used in vessel repair, heart repair and reconstruction, and neonatal repairs; cardiovascular patches; carotid shunts that temporarily shunt the blood to the brain during the removal of plaque in a carotid endarterectomy surgery; biosynthetic vascular graft indicated for lower extremity bypass and dialysis access; and vascular grafts used to bypass or replace diseased arteries. In addition, it offers radiopaque tape, a medical-grade tape applied to the skin that enables surgeons and interventionalists to cross-refer between the inside and the outside of a patient’s body and allows them to locate tributaries or lesions beneath the skin. Further, the company provides valvulotomes, which cut or disrupt valves in the saphenous vein to function as an artery to carry blood past diseased arteries to the lower leg or the foot; and closure systems to attach vessels to one another with titanium clips instead of sutures. It markets its products through a direct sales force and distributors. The company was formerly known as Vascutech, Inc. and changed its name to LeMaitre Vascular, Inc. in April 2001. LeMaitre Vascular, Inc. was incorporated in 1983 and is headquartered in Burlington, Massachusetts.